PROCTER & GAMBLE CoPG
PROCTER & GAMBLE Co Financial Overview 2021–2025
Procter & Gamble delivered a striking divergence in FY2025, generating a 10% jump in operating income to $20.5 billion despite net sales growing a meager 0.3%. This performance underpins a defensive investment thesis relying on aggressive pricing leverage and cost discipline rather than volume expansion to drive shareholder value. As consumer demand softens, the company has turned inward to protect margins, launching a restructuring program in June 2025 aimed at eliminating up to 7,000 non-manufacturing roles and incurring pre-tax charges of up to $1.6 billion.
The company’s top-line trajectory remains steady but slow, with revenue climbing from $76.1 billion in FY2021 to $84.3 billion in FY2025. To offset sluggish organic growth, management prioritizes capital efficiency, repurchasing $6.5 billion in shares during FY2025 and maintaining 102% adjusted free cash flow productivity in Q1 FY2026. While the Health Care segment remained resilient, the Beauty segment faced headwinds with a 2% sales decline in FY2025, driven by weakness in the SK-II brand. By Q2 FY2026, revenue growth remained tepid at 1%, with restructuring costs weighing on short-term net earnings. The market priced this low-volatility reliability at 24.5x earnings at the close of FY2025.
Recent Developments (Q1 and Q2 2026)
Procter & Gamble faced distinct volatility in the first half of FY2026. While net earnings surged 20% in the first quarter due to easier comparisons, momentum stalled by Q2 2026, with revenue growing just 1% to $22.2 billion and diluted EPS slipping 5% to $1.78. Profitability remained under pressure as gross margins contracted due to unfavorable product mix and significant restructuring costs, which totaled $369 million in the second quarter alone. Additionally, the company announced the retirement of Health Care CEO Jennifer Davis effective June 2026, signaling a major leadership transition in a key segment.
Bulls highlight strong cash discipline, evidenced by the $1.06 quarterly dividend and $2.25 billion in new debt raised in November 2025 to bolster liquidity. However, bears are concerned that unit volumes turned negative in the second quarter, suggesting limits to pricing leverage. The stock traded at 23.1x earnings as of January 22, 2026, a slight contraction reflecting the recent earnings dip.
What to watch: organic volume recovery versus pricing reliance; execution of the Health Care division succession.
Rev
$84.28B
FY2025
NI
$15.97B
FY2025
EPS
$6.67
FY2025
OCF
$17.82B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
PROCTER & GAMBLE Co 8-K Report, Regulation FD Disclosure (Jan 22, 2026)
Procter & Gamble (PG) has filed a Current Report on Form 8-K, primarily disclosing information related to its second quarter financial results for fiscal year 2026. The company issued a press release on January 22, 2026, to announce these results and subsequently held a conference call with investors. This 8-K filing is being furnished under Regulation FD to provide transparency regarding the information shared during these communications. Investors should note that the core of this filing consists of informational slides that were referenced during the conference call and are also available on the company's website. The purpose of this disclosure is to ensure that all material information regarding the second quarter performance is disseminated equally to all market participants.
PROCTER & GAMBLE Co 8-K Report, Financial Results (Jan 22, 2026)
Procter & Gamble (PG) has filed a Current Report on Form 8-K to disclose its financial results for the quarter ended December 31, 2025. This filing primarily serves to furnish the accompanying news release, which contains the detailed earnings information investors would typically seek. Investors should review this news release for crucial updates on the company's revenue, profitability, and any management commentary regarding performance drivers and outlook. The report indicates that the company is providing this information under Item 2.02, focusing on results of operations and financial condition for the specified period. While the 8-K itself is a procedural filing, the attached news release is the substantive document containing the financial performance data. Investors should pay close attention to key metrics such as sales growth, earnings per share (EPS), and any changes in segment performance. Management's discussion within the release will likely offer insights into factors influencing these results, including market trends, competitive landscape, and strategic initiatives. This information is vital for assessing the company's ongoing operational health and its ability to meet future financial targets.
PROCTER & GAMBLE Co 8-K Report, Regulation FD Disclosure (Jan 13, 2026)
The Procter & Gamble Company (PG) has filed a Current Report on Form 8-K, primarily to announce a regular quarterly dividend declaration. The Board of Directors has approved a dividend of $1.0568 per share for both its Common Stock and its Series A and Series B ESOP Convertible Class A Preferred Stock. This dividend is scheduled to be paid on or after February 17, 2026, with record dates set for January 23, 2026, for both classes of shareholders. This disclosure is made in accordance with Regulation FD to ensure fair and timely dissemination of material information to all investors.
PROCTER & GAMBLE Co 8-K Report, Executive Changes (Dec 15, 2025)
Procter & Gamble Co. (PG) has filed an 8-K report on December 15, 2025, announcing a significant leadership change. Jennifer Davis, the current Chief Executive Officer of the Health Care division, has informed the company of her intention to retire effective June 30, 2026. Ms. Davis has had a long and distinguished career at P&G, spanning over 33 years, contributing significantly to the company's operations, particularly within the Health Care segment.
PROCTER & GAMBLE Co 8-K Report, Corporate Update (Nov 4, 2025)
Procter & Gamble Co. (PG) announced the successful closing of a public offering for $258.89 million in Floating Rate Notes due November 4, 2075. This offering was conducted under the company's existing Registration Statement on Form S-3. The issuance of these long-term notes signifies a strategic move to secure long-dated financing, likely to support ongoing operations, strategic investments, or capital allocation strategies. Investors should note the floating rate nature of the notes, which means interest payments will adjust over time based on prevailing market rates, potentially impacting future interest expense predictability.
View all 8-K filings →